Eli Lilly is preparing to expand its presence in women’s health, using the enormous financial success of its diabetes and weight-loss medicines to help fund investments in new areas of medicine.
The pharmaceutical giant has been laying the groundwork for a broader women’s health strategy, bringing together specialists and searching for potential new treatments across several conditions, according to people familiar with the plans.
Among the areas attracting Lilly’s attention are bone health and endometriosis, suggesting the company is exploring opportunities beyond the metabolic diseases that have powered its recent growth.
The strategy reflects how Lilly is beginning to deploy the financial windfall generated by its highly successful GLP-1-based diabetes and obesity treatments.
Rather than relying exclusively on the continued expansion of those medicines, the company is looking for new drugs and therapeutic areas that could become future sources of growth.
The push into women’s health is particularly notable because conditions affecting women have historically received less investment and research attention than many other major areas of medicine.
For Lilly, the expansion could therefore serve two purposes: broadening its pharmaceutical pipeline while targeting areas where significant unmet medical needs and opportunities for new treatments remain.
The move also illustrates a larger challenge facing the company following the extraordinary commercial success of its weight-loss and diabetes portfolio — determining how to turn today’s GLP-1 windfall into the medicines and businesses that could drive its next phase of growth.
